Academic Journal
Προβολή σε EDS

Molecular landscape and clinical outcome of SRSF2/TET2 Co-mutated myeloid neoplasms.

Λεπτομέρειες βιβλιογραφικής εγγραφής
Τίτλος: Molecular landscape and clinical outcome of SRSF2/TET2 Co-mutated myeloid neoplasms.
Συγγραφείς: Cockey, Samuel G., Zhang, Hailing, Hussaini, Mohammed, Zhang, Ling, Moscinski, Lynn, Yang, Ethan, Li, Julie, Wang, Le, Song, Jinming
Πηγή: Leukemia & Lymphoma; Mar2025, Vol. 66 Issue 3, p469-478, 10p
Θεματικοί όροι: Treatment effectiveness, Chronic leukemia, Myeloproliferative neoplasms, Overall survival, Myelodysplastic syndromes
Περίληψη: The mutations in SRSF2 and TET2 genes are frequently present in various myeloid neoplasms. The potential impact of SRSF2/TET2 co-mutations on patient survival is incompletely understood. We identified 412 patients with SRSF2/TET2 co-mutations from our NextGen sequencing database of around 8000 patients and reported likely the largest cohort study. Our study demonstrated the presence of these co-mutations in a spectrum of myeloid neoplasms, which show different genetic and molecular characteristics. Most of the patients with these co-mutations had normal karyotype. Interestingly, our study provided insights into the prevalence of additional mutations such as ASXL1, RUNX1, and KRAS with this co-mutation and their potential impact on patients' prognosis. We found that ASXL1, RUNX1, and KRAS can negatively impact these patients' survival with different impacts in different morphological diagnosis categories, suggesting a complex interaction between these genes. This study underscores the need for personalized approaches in the treatment of myeloid neoplasms. [ABSTRACT FROM AUTHOR]
Copyright of Leukemia & Lymphoma is the property of Taylor & Francis Ltd and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Βάση Δεδομένων: Complementary Index
FullText Text:
  Availability: 0
Header DbId: edb
DbLabel: Complementary Index
An: 183197144
RelevancyScore: 994
AccessLevel: 6
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 993.542846679688
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Molecular landscape and clinical outcome of SRSF2/TET2 Co-mutated myeloid neoplasms.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AR" term="%22Cockey%2C+Samuel+G%2E%22">Cockey, Samuel G.</searchLink><br /><searchLink fieldCode="AR" term="%22Zhang%2C+Hailing%22">Zhang, Hailing</searchLink><br /><searchLink fieldCode="AR" term="%22Hussaini%2C+Mohammed%22">Hussaini, Mohammed</searchLink><br /><searchLink fieldCode="AR" term="%22Zhang%2C+Ling%22">Zhang, Ling</searchLink><br /><searchLink fieldCode="AR" term="%22Moscinski%2C+Lynn%22">Moscinski, Lynn</searchLink><br /><searchLink fieldCode="AR" term="%22Yang%2C+Ethan%22">Yang, Ethan</searchLink><br /><searchLink fieldCode="AR" term="%22Li%2C+Julie%22">Li, Julie</searchLink><br /><searchLink fieldCode="AR" term="%22Wang%2C+Le%22">Wang, Le</searchLink><br /><searchLink fieldCode="AR" term="%22Song%2C+Jinming%22">Song, Jinming</searchLink>
– Name: TitleSource
  Label: Source
  Group: Src
  Data: Leukemia & Lymphoma; Mar2025, Vol. 66 Issue 3, p469-478, 10p
– Name: Subject
  Label: Subject Terms
  Group: Su
  Data: <searchLink fieldCode="DE" term="%22Treatment+effectiveness%22">Treatment effectiveness</searchLink><br /><searchLink fieldCode="DE" term="%22Chronic+leukemia%22">Chronic leukemia</searchLink><br /><searchLink fieldCode="DE" term="%22Myeloproliferative+neoplasms%22">Myeloproliferative neoplasms</searchLink><br /><searchLink fieldCode="DE" term="%22Overall+survival%22">Overall survival</searchLink><br /><searchLink fieldCode="DE" term="%22Myelodysplastic+syndromes%22">Myelodysplastic syndromes</searchLink>
– Name: Abstract
  Label: Abstract
  Group: Ab
  Data: The mutations in SRSF2 and TET2 genes are frequently present in various myeloid neoplasms. The potential impact of SRSF2/TET2 co-mutations on patient survival is incompletely understood. We identified 412 patients with SRSF2/TET2 co-mutations from our NextGen sequencing database of around 8000 patients and reported likely the largest cohort study. Our study demonstrated the presence of these co-mutations in a spectrum of myeloid neoplasms, which show different genetic and molecular characteristics. Most of the patients with these co-mutations had normal karyotype. Interestingly, our study provided insights into the prevalence of additional mutations such as ASXL1, RUNX1, and KRAS with this co-mutation and their potential impact on patients' prognosis. We found that ASXL1, RUNX1, and KRAS can negatively impact these patients' survival with different impacts in different morphological diagnosis categories, suggesting a complex interaction between these genes. This study underscores the need for personalized approaches in the treatment of myeloid neoplasms. [ABSTRACT FROM AUTHOR]
– Name: Abstract
  Label:
  Group: Ab
  Data: <i>Copyright of Leukemia & Lymphoma is the property of Taylor & Francis Ltd and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract.</i> (Copyright applies to all Abstracts.)
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=edb&AN=183197144
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1080/10428194.2024.2432581
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        PageCount: 10
        StartPage: 469
    Subjects:
      – SubjectFull: Treatment effectiveness
        Type: general
      – SubjectFull: Chronic leukemia
        Type: general
      – SubjectFull: Myeloproliferative neoplasms
        Type: general
      – SubjectFull: Overall survival
        Type: general
      – SubjectFull: Myelodysplastic syndromes
        Type: general
    Titles:
      – TitleFull: Molecular landscape and clinical outcome of SRSF2/TET2 Co-mutated myeloid neoplasms.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Cockey, Samuel G.
      – PersonEntity:
          Name:
            NameFull: Zhang, Hailing
      – PersonEntity:
          Name:
            NameFull: Hussaini, Mohammed
      – PersonEntity:
          Name:
            NameFull: Zhang, Ling
      – PersonEntity:
          Name:
            NameFull: Moscinski, Lynn
      – PersonEntity:
          Name:
            NameFull: Yang, Ethan
      – PersonEntity:
          Name:
            NameFull: Li, Julie
      – PersonEntity:
          Name:
            NameFull: Wang, Le
      – PersonEntity:
          Name:
            NameFull: Song, Jinming
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 03
              Text: Mar2025
              Type: published
              Y: 2025
          Identifiers:
            – Type: issn-print
              Value: 10428194
          Numbering:
            – Type: volume
              Value: 66
            – Type: issue
              Value: 3
          Titles:
            – TitleFull: Leukemia & Lymphoma
              Type: main
ResultId 1